Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs
Purpose The purpose of this study was to assess the overall burden of pancreatic cancer in
Europe, with a focus on survival time in a real-world setting, and the overall healthy life lost …
Europe, with a focus on survival time in a real-world setting, and the overall healthy life lost …
Epidemiology of and risk factors for pancreatic cancer
EB Gold, SB Goldin - Surgical oncology clinics of North America, 1998 - Elsevier
In the United States, incidence of and mortality from pancreatic cancer increased for several
decades earlier in this century but have tended to level off in recent years. Rates increase …
decades earlier in this century but have tended to level off in recent years. Rates increase …
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
Background The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We
report the final results of the European Study Group for Pancreatic Cancer 1 Trial and …
report the final results of the European Study Group for Pancreatic Cancer 1 Trial and …
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with …
SR Bramhall, J Schulz, J Nemunaitis, PD Brown… - British journal of …, 2002 - nature.com
Pancreatic cancer is the fifth most common cause of cancer death in the western world and
the prognosis for unresectable disease remains poor. Recent advances in conventional …
the prognosis for unresectable disease remains poor. Recent advances in conventional …
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial
SR Bramhall, A Rosemurgy, PD Brown… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: The prognosis for unresectable pancreatic cancer remains dismal (1-year
survival rate,< 10%; 5-year survival rate,< 5%). Recent advances in conventional …
survival rate,< 10%; 5-year survival rate,< 5%). Recent advances in conventional …
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic …
CJ Bruns, CC Solorzano, MT Harbison, S Ozawa… - Cancer …, 2000 - aacrjournals.org
We determined whether down-regulation of the epidermal growth factor-receptor (EGF-R)
signaling pathway by oral administration of a novel EGF-R tyrosine kinase inhibitor (PKI166) …
signaling pathway by oral administration of a novel EGF-R tyrosine kinase inhibitor (PKI166) …
Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units
JP Neoptolemos, RCG Russell… - British Journal of …, 1997 - Wiley Online Library
Background Recent studies have suggested that the mortality rate from pancreatic resection
for cancer is high in the UK compared with that in published series. A survey of specialist …
for cancer is high in the UK compared with that in published series. A survey of specialist …
Occupational exposures and pancreatic cancer: a meta-analysis
IA Ojajärvi, TJ Partanen, A Ahlbom… - Occupational and …, 2000 - oem.bmj.com
OBJECTIVES Consolidation of epidemiological data on pancreatic cancer and worksite
exposures. METHODS Publications during 1969–98 were surveyed. Studies without verified …
exposures. METHODS Publications during 1969–98 were surveyed. Studies without verified …
Inhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and Metastasis
AP Singh, N Moniaux, SC Chauhan, JL Meza… - Cancer …, 2004 - aacrjournals.org
The MUC4 mucin is a high molecular weight membrane-bound glycoprotein. It is aberrantly
expressed in pancreatic tumors and tumor cell lines with no detectable expression in the …
expressed in pancreatic tumors and tumor cell lines with no detectable expression in the …
Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts …
LE Jones, MJ Humphreys, F Campbell… - Clinical Cancer …, 2004 - aacrjournals.org
Purpose: To enable the design of improved inhibitors of matrix metalloproteinases (MMPs)
for the treatment of pancreatic cancer, the expression profiles of a range of MMPs and tissue …
for the treatment of pancreatic cancer, the expression profiles of a range of MMPs and tissue …